Compare iShares MSCI ACWI ETF (ACWI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Johnson & Johnson — how do they compare? iShares MSCI ACWI ETF trades at $160.86, while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while iShares MSCI ACWI ETF pays none. Which is the better fit depends on your goals.
| ACWI | JNJ | |
|---|---|---|
52-Week High | $161.44 | $267.24 |
52-Week Low | $132.04 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $161.65, up 0.34% today, with strong technical momentum showing bullish moving average signals. The ETF benefits from robust global earnings growth and investor inflows into equity ETFs, particularly in technology sectors. Recent institutional activity includes Bank of New York Mellon adjusting its position, while technical indicators show overbought conditions with RSI above 74.
The outlook remains positive given strong EPS growth and reasonable valuation at 15.5x forward P/E. Key risks include overbought technical conditions and market concentration in technology. Institutional sentiment appears constructive with continued ETF inflows supporting the global equity rally.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
